Anna Mowry Acquires 15,000 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CFO Anna Mowry purchased 15,000 shares of the company's stock in a transaction dated Thursday, May 29th. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $11,550.00. Following the transaction, the chief financial officer now owns 83,000 shares of the company's stock, valued at approximately $63,910. This trade represents a 22.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Nautilus Biotechnology Price Performance

NAUT stock traded up $0.03 on Friday, reaching $0.77. 234,003 shares of the company were exchanged, compared to its average volume of 120,566. Nautilus Biotechnology, Inc. has a 12 month low of $0.66 and a 12 month high of $3.09. The stock's fifty day moving average price is $0.76 and its 200 day moving average price is $1.35. The firm has a market capitalization of $97.01 million, a PE ratio of -1.37 and a beta of 1.43.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. As a group, research analysts expect that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

Hedge Funds Weigh In On Nautilus Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth $28,000. XTX Topco Ltd bought a new stake in Nautilus Biotechnology in the 1st quarter valued at $31,000. Cubist Systematic Strategies LLC bought a new stake in Nautilus Biotechnology in the 4th quarter valued at $34,000. Fayez Sarofim & Co bought a new stake in Nautilus Biotechnology in the 1st quarter valued at $39,000. Finally, Squarepoint Ops LLC bought a new stake in Nautilus Biotechnology in the 4th quarter valued at $44,000. Institutional investors own 50.71% of the company's stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.